SRC
MOLECULAR TARGETSRC proto-oncogene, non-receptor tyrosine kinase
SRC (SRC proto-oncogene, non-receptor tyrosine kinase) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting SRC
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Dasatinib | 1.79 | 5 |
| 2 | Resveratrol | 1.39 | 3 |
| 3 | tyrphostin ag 1478 | 1.39 | 3 |
| 4 | Sorafenib | 1.10 | 2 |
| 5 | Quercetin | 0.69 | 1 |
| 6 | Adenosine Monophosphate Adenine nucleotide containing | 0.69 | 1 |
| 7 | Afatinib | 0.69 | 1 |
| 8 | alsterpaullone | 0.69 | 1 |
| 9 | Crizotinib | 0.69 | 1 |
| 10 | kenpaullone | 0.69 | 1 |
| 11 | monorden | 0.69 | 1 |
| 12 | Niclosamide | 0.69 | 1 |
About SRC as a Drug Target
SRC (SRC proto-oncogene, non-receptor tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented SRC interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
SRC inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.